EA201890587A1 - Композиции и способы для лечения боли - Google Patents

Композиции и способы для лечения боли

Info

Publication number
EA201890587A1
EA201890587A1 EA201890587A EA201890587A EA201890587A1 EA 201890587 A1 EA201890587 A1 EA 201890587A1 EA 201890587 A EA201890587 A EA 201890587A EA 201890587 A EA201890587 A EA 201890587A EA 201890587 A1 EA201890587 A1 EA 201890587A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hybrid proteins
toxins
methods
treating pain
compositions
Prior art date
Application number
EA201890587A
Other languages
English (en)
Russian (ru)
Inventor
Р. Джон Коллир
Исаак Чиу
Бредли Л. Пентилут
Кит Ален Фостер
Шилпа Палан
Сай Ман Лю
Original Assignee
Президент Энд Феллоуз Оф Гарвард Колледж
Массачусетс Инститьют Оф Текнолоджи
Ипсен Фарма С.А.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Президент Энд Феллоуз Оф Гарвард Колледж, Массачусетс Инститьют Оф Текнолоджи, Ипсен Фарма С.А.С. filed Critical Президент Энд Феллоуз Оф Гарвард Колледж
Publication of EA201890587A1 publication Critical patent/EA201890587A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EA201890587A 2015-08-27 2016-08-26 Композиции и способы для лечения боли EA201890587A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562210610P 2015-08-27 2015-08-27
PCT/US2016/049106 WO2017035508A1 (fr) 2015-08-27 2016-08-26 Compositions et procédés de traitement de la douleur

Publications (1)

Publication Number Publication Date
EA201890587A1 true EA201890587A1 (ru) 2018-09-28

Family

ID=58101095

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890587A EA201890587A1 (ru) 2015-08-27 2016-08-26 Композиции и способы для лечения боли

Country Status (11)

Country Link
US (4) US11753633B2 (fr)
EP (2) EP3341392A4 (fr)
JP (2) JP2018525021A (fr)
KR (2) KR20180050679A (fr)
CN (2) CN108602861A (fr)
AU (2) AU2016312685A1 (fr)
BR (2) BR112018003782A2 (fr)
CA (2) CA2994729A1 (fr)
EA (1) EA201890587A1 (fr)
MX (1) MX2018002183A (fr)
WO (2) WO2017035507A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
CN108602861A (zh) 2015-08-27 2018-09-28 哈佛大学校长及研究员协会 用于治疗疼痛的组合物和方法
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
MX2019000151A (es) * 2016-07-08 2019-08-29 Childrens Medical Center Una neurotoxina botulinica novedosa y sus derivados.
JP2021500871A (ja) * 2017-09-29 2021-01-14 ザ チルドレンズ メディカル センター コーポレーション ニューロトキシン様トキシンおよびそれらの使用
CA3220194A1 (fr) 2018-01-29 2019-08-01 Ipsen Biopharm Limited Neurotoxines botuliques de clivage de snare non neuronales
EP3752128A1 (fr) * 2018-02-16 2020-12-23 Bontana Therapies Gmbh Neurotoxine botulique reposant sur un acide nucléique, pour application thérapeutique
CA3101481A1 (fr) * 2018-05-30 2019-12-05 The Governing Council Of The University Of Toronto Procedes et kits pour identifier une proteine associee a des interactions recepteur-ligand
WO2020116686A1 (fr) * 2018-12-06 2020-06-11 고려대학교 산학협력단 Récepteur antigénique chimérique anti-antxr humain et utilisations de celui-ci
WO2021150581A2 (fr) * 2020-01-21 2021-07-29 Trustees Of Dartmouth College Variants de chaîne légère de toxine botulique à optimisation immunologique
WO2021156890A2 (fr) * 2020-02-03 2021-08-12 Premas Biotech Private Limited Plateforme d'expression recombinante, constructions et méthodes d'expression de protéines difficiles à exprimer (dte-p)
WO2021173916A1 (fr) * 2020-02-27 2021-09-02 President And Fellows Of Harvard College Immunosurveillance du cancer par la régulation des neurones nocicepteurs
KR20240051355A (ko) * 2022-10-12 2024-04-22 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US20030202989A1 (en) 1995-12-13 2003-10-30 R. John Collier Use of toxin peptides and/or affinity handles for delivering compounds into cells
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
US6767896B1 (en) 1999-01-29 2004-07-27 Cognetix, Inc. Conotoxin peptides
DE60032367T3 (de) 1999-08-25 2011-03-10 Allergan, Inc., Irvine Aktivierbare rekombinante neurotoxine
DE60016256T2 (de) 1999-09-24 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Mutierte Anthraxtoxin Schutz-Antigenproteinen spezifisch für Zellen, die hohe Zelloberflächenmetalloproteinasen- oder Plasminogenaktivator-Rezeptoren-Menge enthalten
EP1246635A4 (fr) 1999-12-30 2004-09-01 Univ Utah Res Found Peptides designes superfamille o- de conotoxines
AU2003237528A1 (en) * 2002-06-07 2003-12-22 Kentucky Bioprocessing, Llc Flexible vaccine assembly and vaccine delivery platform
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
CA2599723A1 (fr) 2005-03-04 2006-09-14 Biorexis Pharmaceutical Corporation Proteines hybrides modifiees de transferrine
ATE463506T1 (de) 2005-09-19 2010-04-15 Allergan Inc Mit clostriedientoxin aktivierbare clostridientoxine
AU2006313493B2 (en) 2005-11-08 2012-11-01 Activen Sa Mu-conotoxin peptides and use thereof as a local anesthetic
EP2001902B1 (fr) 2006-03-14 2013-03-27 Allergan, Inc. Toxines clostridiales modifiées présentant des capacités de ciblage modifiées destinées à des cellules cibles de toxines clostridiales
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
EP2038298A2 (fr) 2006-07-11 2009-03-25 Allergan, Inc. Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules cibles des toxines clostridiennes
AU2007272517B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
US9284358B2 (en) 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
CA2824154A1 (fr) 2011-01-10 2012-07-19 President And Fellows Of Harvard College Procede pour administrer des agents dans des cellules a l'aide de toxines bacteriennes
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
WO2013126690A1 (fr) * 2012-02-23 2013-08-29 President And Fellows Of Harvard College Récepteur de toxine microbienne modifiée pour administration d'agents dans des cellules
EP2852619A4 (fr) 2012-05-21 2016-04-27 Massachusetts Inst Technology Translocation d'entités chimiques artificielles par un pore d'antigène protecteur contre l'anthrax
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
WO2014088928A1 (fr) 2012-12-03 2014-06-12 President And Fellows Of Harvard College Procédés de production de toxines protéiques ciblées par ligature de protéines à médiation par la sortase
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
CN108602861A (zh) 2015-08-27 2018-09-28 哈佛大学校长及研究员协会 用于治疗疼痛的组合物和方法

Also Published As

Publication number Publication date
WO2017035508A1 (fr) 2017-03-02
EP3341392A1 (fr) 2018-07-04
MX2018002183A (es) 2018-05-28
BR112018003782A2 (pt) 2018-09-25
US11104892B2 (en) 2021-08-31
WO2017035507A1 (fr) 2017-03-02
EP3341391A1 (fr) 2018-07-04
CN108602861A (zh) 2018-09-28
CA2994729A1 (fr) 2017-03-02
CA2994560A1 (fr) 2017-03-02
US20220033795A1 (en) 2022-02-03
KR20180070563A (ko) 2018-06-26
KR20180050679A (ko) 2018-05-15
EP3341391A4 (fr) 2019-03-06
AU2016310521A1 (en) 2018-03-01
AU2016312685A1 (en) 2018-03-01
JP2018525021A (ja) 2018-09-06
US10704035B2 (en) 2020-07-07
BR112018003794A2 (pt) 2018-09-25
US20180244731A1 (en) 2018-08-30
EP3341392A4 (fr) 2019-01-23
JP2018530315A (ja) 2018-10-18
US20200362325A1 (en) 2020-11-19
US20180251740A1 (en) 2018-09-06
US11753633B2 (en) 2023-09-12
CN108350039A (zh) 2018-07-31

Similar Documents

Publication Publication Date Title
EA201890587A1 (ru) Композиции и способы для лечения боли
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
PH12018501429A1 (en) Compositions and methods for treating and preventing staphylococcus aureus infections
EA201790465A1 (ru) Антитела, композиции и применение
EA201891028A1 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MY187262A (en) Anti-lag3 antibodies and antigen-binding fragments
EA201691470A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека
EA201691877A1 (ru) Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома
PH12019500929A1 (en) Anti il-33 antibodies and uses thereof
MX2017008643A (es) Proteina de fusion que comprende un dominio de union a ligando de factor de crecimiento endotelial vascular (vegf) y factor de crecimiento derivado de plaquetas (pdgf).
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
PH12019502298A1 (en) Monoclonal antibody to pd-l1
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
NI201900086A (es) Anticuerpos humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo.
EP4079760A3 (fr) Anticorps contre les toxines de clostridium difficile et leurs procédés d'utilisation
PH12014501818A1 (en) Pseudomonas aeruginosa pcrv binding single variable domain antibodies
EA201990222A1 (ru) Антитела к o2 и пути их применения
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2021004772A (es) Variantes de fc5 humanizado y estabilizado para mejorar el transporte de la barrera hematoencefalica.
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
GEP20237484B (en) Antibody variants
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra